Pfizer's 20-valent pneumococcal vaccine hits goal in infant trial, teeing up 2022 approval filing

Pfizer’s 20-valent pneumococcal conjugate vaccine has taken a step toward approval in infants. After four doses, all 20 serotypes met the statistical noninferiority criteria in a study that compared the candidate to Prevnar 13.